Abstract:Zhipeng Zhu, 1, * Xiaoyan Ling, 2, * Hongmei Zhou, 1 Caijun Zhang, 1 Weiwei Yan 1 1 Department of Anesthesiology, The Second Affiliated Hospital of Jiaxing University, Jiaxing City, Zhejiang Province 314000, People's Republic of China; 2 The Outpatient Nursing Department of the Second Affiliated Hospital of Jiaxing University, Jiaxing City, Zhejiang Province 314000, People's Republic of China *These authors contributed equally to this work Correspondence: Zhipeng Zhu Department of Anesthesiology and Pain, The Second Affiliated Hospital of Jiaxing University, Jiaxing City, Zhejiang Province, People's Republic of China Email xiaozhu781126@163.com Background: Myocardial ischaemia-reperfusion injury (IRI) has been confirmed to induce endoplasmic reticulum stress (ERS) when myocardial cell function continues to deteriorate to a certain degree. The clinical applications of effective tested strategies are sometimes inconsistent with the applications evaluated in experiments, although reasonable mechanisms and diverse signalling pathways have been broadly explored. Dexmedetomidine (DEX) has been shown to attenuate IRI of the heart in animal studies. This study aimed to determine whether DEX can protect injured cardiomyocytes under hypoxia/reoxygenation (H/R) at the cellular level and whether the mechanism is related to ERS and the p38 MAPK pathway. Methods: H9c2 cells were subjected to H/R or thapsigargin (TG) to build a model. DEX or 4-PBA was added to the medium either 1 h or 24 h before modelling, respectively. Model parameters were determined by assessing cell viability and injury, which were measured by assessing cell counting kit-8 (CCK8), lactate dehydrogenase (LDH) release and flow cytometry results, and the expression of GRP78, CHOP and caspase-12. In addition, the protein expression of p38MAPK and p-p38MAPK was examined, and SB202190, a negative regulator, was also preincubated in medium. Results: Compared to that of cells in the control group, the activity of cells in the H/R and TG groups was decreased dramatically, and the LDH concentration and proportion of apoptotic cells were increased. DEX could correspondingly reverse the changes induced by H/R or TG. Additionally, DEX effectively attenuated ERS defined as increased expression of GRP78, CHOP and caspase-12. Additionally, DEX could obviously depress the P38 MAPK phosphorylation and high p-p38 MAPK expression in the TG group, indicating DEX has a function similar to that of SB202190. Conclusion: H/R injury in H9c2 cells can lead to abnormal ERS and apoptosis, as well as activation of the p38MAPK signalling pathway. DEX can protect cardiomyocytes by intervening in ERS, regulating p38MAPK and the downstream apoptotic signalling pathway. Keywords: dexmedetomidine, hypoxia/reoxygenation injury, endoplasmic reticulum stress signalling pathway, p38 mitogen-activated protein kinase

Dexmedetomidine Prevents Septic Myocardial Dysfunction in Rats Via Activation of Α7nachr and PI3K/Akt- Mediated Autophagy.

Dexmedetomidine Regulates Exosomal Mir-29B-3p from Macrophages and Alleviates Septic Myocardial Injury by Promoting Autophagy in Cardiomyocytes Via Targeting Glycogen Synthase Kinase 3Β

Both PI3K/Akt and ERK1/2 Pathways Participate in the Protection by Dexmedetomidine Against Transient Focal Cerebral Ischemia/reperfusion Injury in Rats

Dexmedetomidine Ameliorates Cardiac Ischemia/Reperfusion Injury by Enhancing Autophagy Through Activation of the AMPK/SIRT3 Pathway

The Protective Mechanism of Dexmedetomidine in Regulating Atg14L-Beclin1-Vps34 Complex Against Myocardial Ischemia-Reperfusion Injury

Dexmedetomidine Ameliorates Myocardial Ischemia-Reperfusion Injury Through Regulating FASN-associated Cholesterol Homeostasis

Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis Through Inhibiting Endoplasmic Reticulum Stress Signaling

Dexmedetomidine Protects Mice Against Myocardium Ischaemic/reperfusion Injury by Activating an AMPK/PI3K/Akt/eNOS Pathway.

Posttreatment with Dexmedetomidine Aggravates LPS-induced Myocardial Dysfunction Partly Via Activating Cardiac Endothelial Α2a-Ar in Mice.

Dexmedetomidine post-treatment exacerbates metabolic disturbances in septic cardiomyopathy via α2A-adrenoceptor

Dexmedetomidine Protects Against Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through Inhibition of the PI3K/AKT/mTOR Pathway

Dexmedetomidine improves cardiac function and protects against maladaptive remodeling following myocardial infarction.

Dexmedetomidine Attenuates Inflammatory Reaction in the Lung Tissues of Septic Mice by Activating Cholinergic Anti-Inflammatory Pathway

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Liver Oxidative Stress and Cell Apoptosis in Rats by Increasing GSK-3β/MKP-1/Nrf2 Pathway Activity Via the Α2 Adrenergic Receptor.

Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Hyperlipidemic Rats by Inhibiting Inflammation, Oxidative Stress and NF-B

Dexmedetomidine Protects Cardiac Microvascular Endothelial Cells from the Damage of Ogd/r Through Regulation of the Pparδ‐mediated Autophagy

Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus

The Role of Spleen in the Treatment of Experimental Lipopolysaccharide-Induced Sepsis with Dexmedetomidine

Dexmedetomidine Enhances Autophagy <i>via</i> 2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury

Dexmedetomidine Attenuates Cellular Injury and Apoptosis in H9c2 Cardiomyocytes by Regulating p-38MAPK and Endoplasmic Reticulum Stress